Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Policy / Regulatory

NMPA Releases Draft Implementation Rules for the National Key R&D Program – Public Comment Open Through 12 Sept 2026

Fineline Cube Aug 14, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes

Fineline Cube Aug 17, 2026
Company Drug

CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine

Fineline Cube Aug 17, 2026
Company Medical Device

MicroPort MedBot Receives NMPA Approval for Mona Lisa Prostate Puncture Robot System

Fineline Cube May 19, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...

Policy / Regulatory

Liaoning-Led Alliance Launches Volume-Based Procurement Tender for Hernia and Dural Patches

Fineline Cube May 19, 2023

A 12-strong provincial procurement alliance, spearheaded by Liaoning province, has announced the initiation of a...

Company Deals

Asieris Pharmaceuticals Secures Exclusive Global Rights to UroViu’s Fluorescent Imaging Cystoscope

Fineline Cube May 19, 2023

China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced a strategic collaboration with US...

Company Drug

Abbisko Therapeutics and X4 Pharmaceuticals Announce Positive Phase III Results for Mavorixafor in WHIM Syndrome

Fineline Cube May 19, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) and its US partner X4 Pharmaceuticals Inc....

Company Deals

Shenzhen Kangtai Biological Partners with Saudi Importer for Pneumonia Vaccine Distribution

Fineline Cube May 19, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with...

Company Drug

FibroGen’s Roxadustat Shows Positive Results in Phase III Chemotherapy-Induced Anemia Trial

Fineline Cube May 19, 2023

US-based FibroGen Inc. (NASDAQ: FGEN) has announced positive topline data from a Phase III trial...

Company

GenScipt Biotech Corp. Expands Oligonucleotide and Peptide Manufacturing in Zhenjiang

Fineline Cube May 19, 2023

China-based Contract Development and Manufacturing Organization (CDMO) GenScipt Biotech Corp. (HKG: 1548) has revealed the...

Company Drug

NMPA Approves Nanjing Sanhome’s Alfosbuvir for Chronic Hepatitis C Treatment

Fineline Cube May 18, 2023

Nanjing Sanhome Pharmaceutical Co., Ltd has announced that its Category 1 drug alfosbuvir has been...

Company Drug

Betta Pharmaceuticals Initiates Phase I/II Study for First-In-Class BsAb BPB-101

Fineline Cube May 18, 2023

China’s Betta Pharmaceuticals (SHE: 300558) has announced the enrollment of the first patient in a...

Company Drug

Antengene’s First-in-Class CD24 mAb ATG-031 Gets US FDA Approval for Phase I Study

Fineline Cube May 18, 2023

Antengene Corp., Ltd (HKG: 6996) has announced that it has received approval from the US...

Company Drug

BioRay Pharmaceutical’s Zuberitamab Approved by NMPA for CD20 Positive DLBCL Treatment

Fineline Cube May 18, 2023

BioRay Pharmaceutical Co., Ltd has announced that its drug zuberitamab has been approved by the...

Company Drug

WestVac Biopharma Receives FDA Approval for COVID-19 Protein Vaccines Targeting XBB Variants

Fineline Cube May 18, 2023

Chengdu-based WestVac Biopharma Co., Ltd has announced receiving clinical trial approval from the National Medical...

Company Drug

CARSgen Therapeutics Initiates Phase II Study for CT041 in Advanced Gastric Cancer

Fineline Cube May 18, 2023

China-based chimeric antigen receptor (CAR)-T cell specialist CARSgen Therapeutics Holdings Ltd (HKG: 2171) has announced...

Company Deals

National Vaccine & Serum Institute Partners with Corning Life Sciences to Foster Innovation

Fineline Cube May 18, 2023

The National Vaccine & Serum Institute has announced a partnership with Corning Life Sciences, aiming...

Company Drug

CDE Lists Three Home-Grown Drugs for Priority Review, Including Myopia Treatment

Fineline Cube May 18, 2023

The Center for Drug Evaluation (CDE) website has indicated that three home-grown drugs are on...

Company Medical Device

Grand Pharmaceutical’s Novasight Hybrid System Receives Marketing Approval in China

Fineline Cube May 18, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Novasight Hybrid System, a...

Company Deals

HitGen Inc. Enters Research Agreement with ARase Therapeutics to Discover Oncology Inhibitors

Fineline Cube May 18, 2023

China-based HitGen Inc. (SHA: 688222) has announced a research agreement with ARase Therapeutics, Inc. Under...

Company Deals Drug

BeiGene and The Max Foundation Collaborate to Expand Access to Brukinsa for CLL Patients

Fineline Cube May 18, 2023

China-based biotech BeiGene (NASDAQ: BGNE) has formed a collaboration with US-based non-profit organization The Max...

Company Drug

Huadong Medicine’s HDM1002 Receives NMPA Approval for Type 2 Diabetes Clinical Trial

Fineline Cube May 18, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving clinical trial approval from the...

Company Drug

Everest Medicines Completes Patient Enrollment in Etrasimod Phase III UC Trial

Fineline Cube May 17, 2023

Everest Medicines (HKG: 1952), a China-based biopharmaceutical company, has declared the successful completion of patient...

Posts pagination

1 … 567 568 569 … 709

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
  • CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine
  • Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑002, a Brain‑Penetrant BTK PROTAC for B‑Cell Non‑Hodgkin Lymphoma
  • Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets
  • Shanghai Ark Biopharmaceutical Wins FDA Clearance for Ziresovir Phase II Trials in Severe Pediatric RSV
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes

Company Drug

CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine

Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑002, a Brain‑Penetrant BTK PROTAC for B‑Cell Non‑Hodgkin Lymphoma

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.